In psoriasis patients receiving biologic IL-17 therapeutic blockade circulating Th1, Th17 and sub-populations as CXCR3+-Th17 and Th17.1 were decreased as early as 3 months after treatment initiation. This evidence concerns the gene IL17A and psoriasis.